Co-Diagnostics Corp (CODX): רווח נקי למניה (EPS TTM)

Co-Diagnostics, Inc. (CODX) is scaling test deliveries via outsourcing to avoid plant expenditures, while the humanitarian status of medicine minimizes geopolitical risks. The rolling net income per share metric helps track revenue dynamics, where -18.99 records a new level. Patent protection for PCR methods and strict government certification of diagnostic systems ensure a high barrier to entry.

The high barrier to entry in molecular diagnostics, driven by PCR patents, directly determines the efficiency of net income per share for Co-Diagnostics, Inc. (CODX). This metric aggregates trailing twelve-month income, neutralizing quarterly reporting gaps between 10-Q and 10-K filings. By analyzing changes in trailing net income per share, an investor can discern the actual return on a single unit of capital. This allows for an objective valuation of the asset without time lags. A stable trend confirms the market resilience of Co-Diagnostics, Inc. (CODX).